Khiron Life Sciences Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KHRNF research report →
Price Chart
About the company
Khiron Life Sciences Corp. is an integrated enterprise focusing on medical and cannabis solutions across Latin America and Europe. Its operations are structured into Health Services, Medical Cannabis Products, and Wellbeing Products segments.
- CEO
- Alvaro Francisco Torres
- IPO
- 2021
- Employees
- 310
- HQ
- Vancouver, BC, CA
Get TickerSpark's AI analysis on KHRNF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.32K
- P/E
- -0.20
- Fwd P/E
- 0.00
- PEG
- -0.00
- P/S
- 0.73
- P/B
- 0.20
- EV/EBITDA
- -0.12
- Div Yield
- 0.00%
- Gross Margin
- 22.47%
- Op Margin
- -174.52%
- Net Margin
- -258.92%
- ROE
- -68.62%
- ROIC
- -61.04%
Latest fiscal year · YoY change
- Revenue
- $12.79M+59.6%
- Gross Profit
- $6.37M-9.1%
- Op Income
- $-19,787,000
- Net Income
- $-33,129,000-37.8%
- EPS
- $-0.20+0.0%
- OCF Growth
- +16.8%
- FCF Growth
- +18.7%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 5.43
- RSI (14)
- 52
- Avg Volume
- 9.57K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Khiron’s Q3 revenue was pressured by a temporary pause in Colombian insurance-covered prescriptions, but Europe continued to scale and the company emphasized improving margins, costs, and liquidity.· November 30, 2022
- Q3 revenue was $3.4 million, broadly flat versus Q3 2021 but down $1.1 million sequentially, mainly because insurance-covered prescriptions in Colombia were temporarily interrupted.
- Europe was the standout growth driver: revenue there was $0.9 million, up 141% year over year, led by the UK and supported by the Pharmadrug integration.
- Gross margin was 48%, down from 50.2% in Q2, as lower-margin European sales became a larger mix; Colombia still posted a 76% gross margin.
- Adjusted EBITDA loss improved to $2.8 million, the lowest the company said it had recorded, helped by a Group-wide cost reduction program.
- Management said it expects Q4 Colombian medical cannabis trends to stay affected until the government formalizes financing protocols, while Europe, Germany, the UK, and Switzerland should continue expanding.
Khiron reported Q3 revenue of $3.4 million, broadly flat versus Q3 2021, but down $1.1 million from Q2 2022. Gross profit before fair value adjustments was $1.4 million and gross margin was 48%, compared with 50.2% in Q2; operating expenses were $5.2 million, down $300,000 sequentially and $1.1 million year over year. Adjusted EBITDA loss was $2.8 million versus $3.7 million in Q3 2021; net loss was $3.6 million and comprehensive loss was $4.0 million. Europe revenue was $0.9 million, up 141% year over year, while health services revenue was $1.8 million. Cash outflow from operating activities was $9.8 million year to date, net cash was $1.9 million at quarter end, and financial debt was $0.6 million. Management did not give formal next-quarter or full-year financial guidance, but said Colombia’s insurance framework is still awaiting formalization and that Q4 will likely continue to reflect the temporary disruption there while Europe growth continues.
Alvaro Torres framed the quarter as a short-term setback in Colombia rather than a structural issue, saying the company’s top-line was hurt by a temporary interruption in insurance-covered prescriptions during the government transition. He emphasized that Colombia’s new government is cannabis-friendly, that the business has expanded beyond Colombia into Europe and other Latin American markets, and that Khiron is evolving into a healthcare-focused platform with stronger margins and more diversified geography. His tone was upbeat and defensive at the same time: he acknowledged the near-term disruption, but repeatedly argued that the model, the patient base, and the new government support make the company’s longer-term trajectory intact.
Helen Bellewood focused on the earnings bridge and balance sheet. She said the revenue decline was driven primarily by Colombia’s prescription interruption and also by $300,000 of adverse foreign exchange movement; she noted that medical cannabis represented 47.4% of total revenue versus 58.3% in the prior quarter, and that the trend would continue into Q4 until government financing protocols are formalized. She also highlighted cost discipline, with operating expenses at $5.2 million, adjusted EBITDA loss at $2.8 million, cash outflow from operating activities at $9.8 million year to date, net cash of $1.9 million, total assets excluding goodwill of $32.3 million, inventory of $9.8 million, receivables of $4.5 million, and financial debt of $0.6 million.
The most notable questions centered on Europe’s growth, the impact of Pharmadrug, the timeline for Colombia’s insurance coverage, and the new working capital loan. Management said Pharmadrug is now the backbone of European distribution, that product launches in Germany and the UK were delayed by licensing updates but restarted in late Q3, and that the platform should improve gross margins by allowing direct pharmacy sales. On Colombia, Alvaro said he could not give a definite timing for the insurance framework, but expects it to be resolved in the short term and stressed that more than 35,000 patients have been served there. He also said the investment-grade bank loan validates the healthcare-platform model and the quality of receivables, while Franziska added that Pharmadrug’s Schedule 1 license could potentially support both Khiron products and complementary third-party brands.
The bull case from the call is that the Colombia issue is temporary while Europe is becoming a real growth engine. Management pointed to 141% year-over-year Europe revenue growth, expanding UK clinic momentum, first sales in Switzerland, and Germany restarting through Pharmadrug with better direct-sale margins. The company also highlighted lower operating expenses, a smaller adjusted EBITDA loss, and a working capital loan from a major investment-grade bank as signs that the model is gaining credibility.
The main bear case is that Khiron remains exposed to regulatory and reimbursement disruption in Colombia, which still meaningfully affects revenue and may continue into Q4. Gross margin fell to 48% as the mix shifted toward lower-margin European sales, and the company did not provide a firm timeline for the Colombian insurance framework to return. Investors also have to absorb continuing losses, FX volatility, and the fact that Germany product launches were delayed by license updates, showing execution and regulatory risk remains material.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 88.2%
- Shares Outstanding
- 232.41M
- Float Shares
- 204.94M
Our KHRNF coverage
Recent articles, reports, and earnings notes.
No research on KHRNF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KHRNF report →Khiron Life Sciences Announces Closing of the Sale of Its European Business
newsfilecorp.com · Nov 17
Khiron Life Sciences Announces Update to the Proposed Sale of Its European Business
newsfilecorp.com · Nov 16
KHIRON LIFE SCIENCES ANNOUNCES CEASE TRADE ORDER
headlinesoftoday.com · May 6
Khiron Life Sciences Corp. (KHRNF) Q3 2022 Earnings Call Transcript
seekingalpha.com · Nov 30
Khiron to Host Third Quarter 2022 Conference Call on November 30, 2022
prnewswire.com · Nov 18
Khiron Life Sciences Corp. (KHRNF) Q2 2022 Earnings Call Transcript
seekingalpha.com · Aug 29
PharmaDrug closes sale of German cannabis assets to Khiron Life Sciences
proactiveinvestors.com · Aug 3
Khiron Life Sciences Raises C$4M Via Equity Offering
benzinga.com · Jun 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.